Chronic hepatitis C
Conditions
Interventions
PEG-IFN alfa2a weekly for 24weeks in patients with negative results of HCV RNA test at week4 of therapy (GroupA)
PEG-IFN alfa2a weekly for 48weeks in patients with negative results of HCV RNA test at
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following patients with chronic hepatitis C were eligible to enter the trial 1) The patients were hemodialysis at least 3months and had detectable HCV RNA 2)Serogroup doesn't ask it 3)Neutrophil count >=1,500/mm3.Hemoglobin concentration >10g/dL.Platelet count >=90,000/mm3 4) The presence of the liver biopsy is not asked 5) From 18 years old or over to 70years old or less 6)Patients who provided written informed consents to participate the study prior to enrollment
Exclusion criteria
Exclusion criteria: The following patients were excluded 1)Allegic history to interferon preparations 2)Autoimmune hepatitis,alcoholic liver injury,or chronic liver diseases with other underlying causes 3)Liver cirrhosis,decompensated liver diseases 4) Abnormal thyroid function 5)Concomitant herbal medication of Sho-saikoto 6) history of interstitial pneumonia 7) Women of childbearing potential and pregnancy, lactating woman 8)severe depression 9)Allergic to vaccine or biological preparations 10)Other conditions considered inappropriate by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative result of HCV RNA test at 24 weeks after terminating therapy | — |
Countries
Japan
Outcome results
None listed